Positive results from initial clinical trials of Covid-19 vaccine AZD1222, manufactured by IRBM’s Advent
IRBM’s Advent, a global leader in viral vector manufacturing, has made thousands of doses of a novel Covid-19 vaccine, called AZD1222, for use by the University of Oxford and AstraZeneca in clinical trials in the UK, Brazil and South Africa.
